Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024, before the U.S. financial markets open.